Rheumatic complications in cancer patients treated with immune checkpoint inhibitors

키워드

참고문헌 (63)

1. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
2. Eggermont AM, "Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy", N Engl J Med, 375, pp.1845~1855 (2016)
3. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
4. Robert C, "Nivolumab in previously untreated melanoma without BRAF mutation", N Engl J Med, 372, pp.320~330 (2015)
5. Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
6. Abbas AK, "Cellular and Molecular Immunology" (2018), Elsevier
7. Pauken KE, "Overcoming T cell exhaustion in infection and cancer", Trends Immunol, 36, pp.265~276 (2015)
8. Sharma P, "Immune checkpoint targeting in cancer therapy : toward combination strategies with curative potential", Cell, 161, pp.205~214 (2015)
9. June CH, "Is autoimmunity the Achilles’ heel of cancer immunotherapy?", Nat Med, 23, pp.540~547 (2017)
10. Brahmer JR, "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline", J Clin Oncol, 36, pp.1714~1768 (2018)
11. Eigentler TK, "Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy", Cancer Treat Rev, 45, pp.7~18 (2016)
12. Calabrese LH, "Rheumatic immune-related adverse events from cancer immunotherapy", Nat Rev Rheumatol, 14, pp.569~579 (2018)
13. Ostrand-Rosenberg S, "Immune surveillance : a balance between protumor and antitumor immunity", Curr Opin Genet Dev, 18, pp.11~18 (2008)
14. Schreiber RD, "Cancer immunoediting : integrating immunity’s roles in cancer suppression and promotion", Science, 331, pp.1565~1570 (2011)
15. Zarour HM, "Reversing T-cell dysfunction and exhaustion in cancer", Clin Cancer Res, 22, pp.1856~1864 (2016)
16. Leach DR, "Enhancement of antitumor immunity by CTLA-4 blockade", Science, 271, pp.1734~1736 (1996)
17. Peggs KS, "Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies", J Exp Med, 206, pp.1717~1725 (2009)
18. Ishida Y, "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death", EMBO J, 11, pp.3887~3895 (1992)
19. Dong H, "Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion", Nat Med, 8, pp.793~800 (2002)
20. Postow MA, "Immune checkpoint blockade in cancer therapy", J Clin Oncol, 33, pp.1974~1982 (2015)
21. Vanderlugt CL, "Epitope spreading in immune-mediated diseases : implications for immunotherapy", Nat Rev Immunol, 2, pp.85~95 (2002)
22. Naidoo J, "Toxicities of the anti-PD-1and anti-PD-L1 immune checkpoint antibodies", Ann Oncol, 26, pp.2375~2391 (2015)
23. Oh DY, "Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire", Cancer Res, 77, pp.1322~1330 (2017)
24. Simpson TR, "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma", J Exp Med, 210, pp.1695~1710 (2013)
25. Winer A, "Identifying and managing the adverse effects of immune checkpoint blockade", J Thorac Dis, 10(Suppl 3), pp.S480~S489 (2018)
26. Bowyer S, "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy", Br J Cancer, 114, pp.1084~1089 (2016)
27. Baxi S, "Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs : systematic review and meta-analysis", BMJ, 360, pp.k793~ (2018)
28. Cappelli LC, "Immune-related adverse effects of cancer immunotherapy-implications for rheumatology", Rheum Dis Clin North Am, 43, pp.65~78 (2017)
29. Tocut M, "Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors", Autoimmun Rev, 17, pp.610~616 (2018)
30. Buder-Bakhaya K, "Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies", Cancer Immunol Immunother, 67, pp.175~182 (2018)
31. Bronstein Y, "Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy", AJR Am J Roentgenol, 197, pp.W992~W1000 (2011)
32. Lidar M, "Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors", Autoimmun Rev, 17, pp.284~289 (2018)
33. Johnson DB, "Fulminant myocarditis with combination immune checkpoint blockade", N Engl J Med, 375, pp.1749~1755 (2016)
34. Puzanov I, "Managing toxicities associated with immune checkpoint inhibitors : consensus recommendations from the Society for Immunotherapy of Cancer(SITC)Toxicity Management Working Group", J Immunother Cancer, 5, pp.95~ (2017)
35. Kostine M, "Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response : a single-centre prospective cohort study", Ann Rheum Dis, 77, pp.393~398 (2018)
36. Ohnuma K, "Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy", Mod Rheumatol, 29, pp.721~732 (2019)
37. Ruiz-Banobre J, "Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature", Lung Cancer, 108, pp.217~221 (2017)
38. Law-Ping-Man S, "Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer", Rheumatology(Oxford), 55, pp.2087~2089 (2016)
39. Cappelli LC, "Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab", Ann Rheum Dis, 76, pp.43~50 (2017)
40. Mooradian MJ, "Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy : a single center experience", Semin Arthritis Rheum, 48, pp.1127~1132 (2019)
41. Calabrese C, "Rheumatic immune-related adverse events of checkpoint therapy for cancer : case series of a new nosological entity", RMD Open, 3, pp.e000412~ (2017)
42. Smith MH, "Arthritis after cancer immunotherapy : symptom duration and treatment response", Arthritis Care Res(Hoboken), 71, pp.362~366 (2019)
43. Suarez-Almazor ME, "Review : immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer", Arthritis Rheumatol, 69, pp.687~699 (2017)
44. Selva-O’Callaghan A, "Classification and management of adult inflammatory myopathies", Lancet Neurol, 17, pp.816~828 (2018)
45. Touat M, "Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer", Neurology, 91, pp.e985~e994 (2018)
46. Moreira A, "Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors", Eur J Cancer, 106, pp.12~23 (2019)
47. Haddox CL, "Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm", Ann Oncol, 28, pp.673~675 (2017)
48. Yamaguchi Y, "A case of drug-associated dermatomyositis following ipilimumab therapy", Eur J Dermatol, 26, pp.320~321 (2016)
49. Kimura T, "Myasthenic crisis and polymyositis induced by one dose of nivolumab", Cancer Sci, 107, pp.1055~1058 (2016)
50. Kao JC, "Neurological complications associated with anti-programmed death 1(PD-1)antibodies", JAMA Neurol, 74, pp.1216~1222 (2017)
51. Gonzalez-Gay MA, "Polymyalgia rheumatica", Lancet, 390, pp.1700~1712 (2017)
52. Goldstein BL, "Drug-associated polymyalgia rheumatica", giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4, 2014, pp.66, 768~769
53. Belkhir R, "Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment", Ann Rheum Dis, 76, pp.1747~1750 (2017)
54. Bernier M, "Nivolumab causing a polymyalgia rheumatica in a patient with a squamous non-small cell lung cancer", J Immunother, 40, pp.129~131 (2017)
55. Dasgupta B, "2012 Provisional classification criteria for polymyalgia rheumatica : a European League Against Rheumatism", American College of Rheumatology collaborative initiative, 2012, pp.71, 484~492
56. Champiat S, "Management of immune checkpoint blockade dysimmune toxicities : a collaborative position paper", Ann Oncol, 27, pp.559~574 (2016)
57. Haanen JBAG, "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 29(Supplement_4), pp.iv264~iv266 (2018)
58. Freeman-Keller M, "Nivolumab in resected and unresectable metastatic melanoma : characteristics of immune-related adverse events and association with outcomes", Clin Cancer Res, 22, pp.886~894 (2016)
59. Menzies AM, "Anti-PD-1therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab", Ann Oncol, 28, pp.368~376 (2017)
60. Richter MD, "Brief report : cancer immunotherapy in patients with preexisting rheumatic disease : the Mayo Clinic Experience", Arthritis Rheumatol, 70, pp.356~360 (2018)
61. Johnson DB, "Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders", JAMA Oncol, 2, pp.234~240 (2016)
62. Gutzmer R, "Programmed cell death protein-1(PD-1)inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity", Eur J Cancer, 75, pp.24~32 (2017)
63. Danlos FX, "Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease", Eur J Cancer, 91, pp.21~29 (2018)

관련 논문AI추천